Abstract:Domain-aware artificial intelligence has been increasingly adopted in recent years to expedite molecular design in various applications, including drug design and discovery. Recent advances in areas such as physics-informed machine learning and reasoning, software engineering, high-end hardware development, and computing infrastructures are providing opportunities to build scalable and explainable AI molecular discovery systems. This could improve a design hypothesis through feedback analysis, data integration that can provide a basis for the introduction of end-to-end automation for compound discovery and optimization, and enable more intelligent searches of chemical space. Several state-of-the-art ML architectures are predominantly and independently used for predicting the properties of small molecules, their high throughput synthesis, and screening, iteratively identifying and optimizing lead therapeutic candidates. However, such deep learning and ML approaches also raise considerable conceptual, technical, scalability, and end-to-end error quantification challenges, as well as skepticism about the current AI hype to build automated tools. To this end, synergistically and intelligently using these individual components along with robust quantum physics-based molecular representation and data generation tools in a closed-loop holds enormous promise for accelerated therapeutic design to critically analyze the opportunities and challenges for their more widespread application. This article aims to identify the most recent technology and breakthrough achieved by each of the components and discusses how such autonomous AI and ML workflows can be integrated to radically accelerate the protein target or disease model-based probe design that can be iteratively validated experimentally. Taken together, this could significantly reduce the timeline for end-to-end therapeutic discovery and optimization upon the arrival of any novel zoonotic transmission event. Our article serves as a guide for medicinal, computational chemistry and biology, analytical chemistry, and the ML community to practice autonomous molecular design in precision medicine and drug discovery.

Microscopic Artificial Intelligence: An Artificial Intelligence Research Roadmap for Molecules, Materials and Proteins

Artificial Intelligence for Microbiology and Microbiome Research

Artificial Intelligence in Genomic Sequence, Protein Structure Function Prediction and DNA Microarrays: a Survey

Preface: Paving the Road for AI in Molecular Sciences

Artificial Intelligence for Autonomous Molecular Design: A Perspective

Living cells and biological mechanisms as prototypes for developing chemical artificial intelligence

Artificial intelligence for microbial biotechnology: beyond the hype

AI-enhanced biomedical micro/nanorobots in microfluidics

Artificial Intelligence Enhanced Molecular Simulations.

Advancing microbial production through artificial intelligence-aided biology

Microsystem Advances through Integration with Artificial Intelligence

Progress and Research Trends of Artificial Intelligence Incorporation in Protein Structure Prediction

Application of Artificial Intelligence in Microfluidic Systems

Artificial intelligence: A powerful paradigm for scientific research

Establishing Digital Recognition and Identification of Microscopic Objects for Implementation of Artificial Intelligence (AI) Guided Microassembly

Artificial Intelligence in Pharmaceutical Sciences

Artificial Intelligence is Empowering Chemistry Research

Revolutionizing Molecular Design for Innovative Therapeutic Applications through Artificial Intelligence

The Process of AI-Aided Drug Design

Can AI design life?

A contribution spanning three time periods offered by artificial intelligence and synthetic biology